Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week Looks At 2014 Takeout Targets

Executive Summary

The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.

You may also be interested in...



Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting

The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.

Bristol Gets Five Primed For Immuno-Oncology Expansion

Bristol strengthens its leading role in the immuno-oncology space through a discovery and development collaboration with newly public biotech Five Prime, a deal that could be worth more than $350 million with earn-outs. The pharma also takes an equity stake in its new oncology partner.

Kythera Doubles Down On Double Chins With Bayer Buyback

The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel